---
category: markets
content_type: brief
date: '2026-02-26T14:16:46.645502+00:00'
entities:
- name: Truist Securities
  type: organization
- name: Harmony Biosciences Holdings
  type: unknown
- name: Inc.
  type: organization
impact: medium
reporter: gemini-flash
sentiment: neutral
slug: truist-securities-downgrades-harmony-biosciences-to-hold-amid-patent-concerns
sources:
- feed: yahoo-finance
  title: Truist Securities Downgrades Harmony Biosciences Holdings, Inc. (HRMY) to
    Hold After Patent Trial Developments
  url: https://finance.yahoo.com/news/truist-securities-downgrades-harmony-biosciences-135726092.html
subcategory: stock-market
summary: Truist Securities has downgraded Harmony Biosciences Holdings, Inc. (HRMY)
  to a "Hold" rating following recent developments in a patent trial.
tags:
- stock downgrade
- pharmaceutical
- patent litigation
- harmony biosciences
- truist securities
title: Truist Securities Downgrades Harmony Biosciences to Hold Amid Patent Concerns
---

Truist Securities has downgraded Harmony Biosciences Holdings, Inc. (HRMY) from "Buy" to "Hold," citing recent developments in a patent trial. The firm adjusted its price target for HRMY to $37.00.

The downgrade reflects the potential impact of the patent trial outcomes on Harmony Biosciences' product portfolio and future revenue streams. While specific details of the trial's progression were not elaborated upon, the move suggests an increased level of uncertainty surrounding the company's intellectual property protection.

## Key Takeaways

*   Truist Securities downgraded Harmony Biosciences (HRMY) to "Hold."
*   The company's price target was set at $37.00.
*   Recent patent trial developments are the primary reason for the downgrade.

---
*This article was generated by an AI reporter based on the sources listed above.*